PKF115-584

PKF115-584 is a **small molecule inhibitor** that disrupts the interaction between β-catenin and T cell factor (TCF) in the canonical Wnt signaling pathway. This interaction is critical for the transcription of Wnt target genes, which are commonly deregulated in multiple cancers, including multiple myeloma and adrenocortical carcinoma. PKF115-584 binds to and inhibits the β-catenin/TCF transcriptional complex, leading to downregulation of Wnt target genes such as c-MYC and Cyclin D1, suppression of cell proliferation, cell cycle arrest, and induction of apoptosis in tumor cells that depend on Wnt signaling. In various preclinical models, PKF115-584 reduces tumor growth and increases survival, showing activity against multiple myeloma and adrenocortical carcinoma cell lines, including those resistant to other therapies. The compound does not exhibit cytotoxicity in normal cells not reliant on active Wnt signaling, suggesting potential therapeutic selectivity[1][3][4][7]. PKF115-584 was initially developed by the University of California and remains in the early discovery and preclinical stage[5].